Results 181 to 190 of about 1,019,468 (263)

Effects of CYP2E1 Polymorphism and Dietary Supplementation With Jerusalem Artichoke on Skatole and Indole Levels in the Back Fat and Feces of Boars, and Liver mRNA Expression

Food Science &Nutrition, Volume 14, Issue 9, September 2026.
This study investigated the combined effects of CYP2E1 gene polymorphism (SNP NM_214421.1: c.1423G > A) and short‐term dietary supplementation with Jerusalem artichoke (Helianthus tuberosus, 8.2% tuber meal) on skatole and indole concentrations in back fat and feces of 25 crossbreed boars, and on hepatic CYP2E1 mRNA expression. Animals were assigned to
Kateřina Zadinová, Antonín Stratil, Jaroslav Čítek, Monika Okrouhlá, Jan Calta, Ivan Bahelka, Kateřina Urbancová, Michal Šprysl, Roman Stupka   +8 more
wiley   +1 more source

Urethral Metastasis of Therapy‐Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Urethral metastasis of prostate cancer is exceptionally rare, particularly in castration‐resistant disease. Therapy‐induced neuroendocrine prostate cancer (t‐NEPC) is an aggressive variant with limited treatment options. Case Presentation A 72‐year‐old man, 14 years after diagnosis of prostate adenocarcinoma treated with androgen ...
Toshiaki Kayaba, Satoshi Washino, Takanori Hayase, Kai Yazaki, Kimitoshi Saito, Tomoaki Miyagawa   +5 more
wiley   +1 more source

Use of Meloxicam or Ketoprofen for Piglet Pain Control Following Surgical Castration. [PDF]

Front Vet Sci, 2018
Viscardi AV, Turner PV.
europepmc   +1 more source

Penile Metastasis From Castration‐Resistant Prostate Cancer: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Penile metastasis from prostate cancer—generally associated with a poor prognosis—is rare and underreported. We report one relevant case. Case Presentation The patient was a 65‐year‐old male with metastatic hormone‐sensitive prostate cancer (prostate‐specific antigen [PSA]: 500 ng/mL) and lung, bone, and lymph node metastases. The
Satoshi Asakura, Yoshihiro Nakagami, Tatsuki Inoue, Yuki Matsui, Kazuhiko Oshinomi, Masakazu Nagata, Takashi Fukagai, Yasuyuki Ohira, Yoshiko Yamochi   +8 more
wiley   +1 more source

The age of surgical castration affects the healing process in beef calves. [PDF]

Transl Anim Sci, 2017
Norring M, Mintline EM, Tucker CB.
europepmc   +1 more source

SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 9, September 2026.
SLC3A1 is a promising therapeutic target for advanced prostate cancer. ABSTRACT Prostate cancer (PCa) remains a leading cause of cancer‐related mortality in aging male, with resistance to enzalutamide (Enza) representing a major therapeutic challenge. This study identifies SLC3A1 as a key driver of Enza resistance.
Peng Liu, Haocheng Zhang, Yuhang Qian, Jiong Zhang, Xiaojun Deng, Bin Sun   +5 more
wiley   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

Metabolism in Tumor: Mechanisms and Therapeutic Perspectives

MedComm, Volume 7, Issue 9, September 2026.
Tumor metabolic reprogramming converges on three hubs—the SREBP1/2–FASN–SCD1 lipogenic axis, the HIF‐1α–GLUT1–LDHA glycolytic axis, and the LDLR–SCARB1–LXR cholesterol system—which integrate transcriptional, epigenetic (histone lactylation, m6A), and microenvironmental inputs to generate metabolic plasticity, immune evasion, and therapy resistance ...
Jia‐Chen Cheng, Yi‐Xuan Hu, Xiang‐Chun Huang, Shan Jiang, Jie‐Lin Wang, Yang Zhao, Shuo Chen   +6 more
wiley   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source